Postmenopausal Osteoporosis Annual Evaluation Checklist

Why Annual Evaluation Matters After Menopause

Bone loss does not announce itself. You will not feel your hip losing density between visits. That silence is exactly why a structured annual review is so valuable: it turns invisible biology into actionable numbers before a fracture happens.

Approximately 10 million Americans have osteoporosis, and 80% of them are women. The risk rises steeply after menopause because estrogen normally suppresses osteoclast activity, the cells that break down bone. When estrogen drops, osteoclasts work faster than osteoblasts can rebuild, and women can lose 3-5% of bone mineral density per year in the first few years after their final period.

A structured annual evaluation catches three things early: accelerating bone loss, rising fracture risk, and treatment that is no longer working or no longer needed.

The Difference Between Osteopenia and Osteoporosis

Your DEXA result comes as a T-score. The World Health Organization defines osteoporosis as a T-score at or below −2.5, and osteopenia as a T-score between −1.0 and −2.5. These cutoffs were established in postmenopausal women specifically, using young adult female reference data. Many women in the osteopenia range still qualify for pharmacologic treatment once FRAX is applied.

How This Differs From Premenopausal Bone Loss

In reproductive-age women, estrogen protects bone. Conditions that suppress estrogen, including hypothalamic amenorrhea, premature ovarian insufficiency, and eating disorders, can cause premenopausal osteoporosis. The evaluation logic is similar, but the treatment calculus differs because hormone therapy is both the bone-protective intervention and the standard of care for premature ovarian insufficiency. ACOG recommends hormone therapy for women with POI to protect skeletal health until at least age 51.

Step 1: DEXA Scan Scheduling

Your DEXA schedule depends on your current T-score and clinical risk.

When to Get Your First Scan

The US Preventive Services Task Force recommends routine DEXA screening starting at age 65 for women without known risk factors. For women under 65, screening is recommended when your 10-year fracture probability (calculated by FRAX without BMD) equals or exceeds that of a 65-year-old white woman with no additional risk factors, roughly 9.3%.

Clinical triggers for earlier screening include:

• Early menopause (before age 45) or surgical menopause
• Premature ovarian insufficiency
• Long-term glucocorticoid use (prednisone ≥5 mg/day for three months or more)
• Rheumatoid arthritis, celiac disease, or inflammatory bowel disease
• History of fragility fracture after age 40
• Low body weight (BMI <18.5 kg/m²)
• Parental history of hip fracture

How Often to Repeat

The Menopause Society 2021 position statement advises repeat DEXA every 1-2 years for women on pharmacologic treatment, and every 2-5 years for untreated women, depending on baseline T-score and clinical risk. Women with a baseline T-score close to −2.5 need more frequent monitoring than those at −1.2.

Step 2: FRAX Fracture Risk Calculation

A DEXA T-score alone does not capture your full fracture risk. FRAX integrates clinical risk factors to estimate your 10-year probability of a major osteoporotic fracture (hip, spine, wrist, or shoulder) and of hip fracture specifically.

What Goes Into FRAX

The FRAX tool uses age, sex, weight, height, prior fracture, parental hip fracture, smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis causes, and alcohol use. It can be run with or without femoral neck BMD.

Treatment Thresholds

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) guidelines recommend pharmacologic treatment for postmenopausal women with a FRAX-based 10-year major osteoporotic fracture risk at or above 20%, or a hip fracture risk at or above 3%. These thresholds apply in the US; other countries use country-specific FRAX models and thresholds.

At your annual visit, ask your clinician to run FRAX even if your T-score has not changed. Age alone raises FRAX output year over year.

Step 3: Laboratory Evaluation

Bone loss can have correctable secondary causes. Missing them means treating a symptom while the underlying driver continues.

Core Lab Panel

At minimum, your annual evaluation should include:

• Serum calcium and albumin (to calculate corrected calcium)
• 25-hydroxyvitamin D (target 30-50 ng/mL for bone health)
• Creatinine and eGFR (bisphosphonates require adequate kidney function; avoid if eGFR <30-35 mL/min/1.73 m²)
• Complete blood count (to screen for hematologic causes of bone loss)
• Thyroid-stimulating hormone (subclinical hyperthyroidism accelerates bone loss)
• Serum phosphorus (low phosphorus may indicate osteomalacia)

Vitamin D insufficiency affects an estimated 40% of US adults and is especially common in postmenopausal women with limited sun exposure. Correcting a 25-OH vitamin D level below 20 ng/mL with supplementation and sunlight is a low-cost, low-risk first step before any pharmacologic decision.

When to Add More Testing

Add the following if secondary osteoporosis is suspected:

• Serum and urine protein electrophoresis (multiple myeloma)
• Urine calcium (24-hour) (hypercalciuria or malabsorption)
• Parathyroid hormone (primary hyperparathyroidism)
• Serum testosterone and DHEA-S (if androgen deficiency is a factor, relevant in surgical menopause)
• Celiac antibodies (tTG-IgA) (malabsorptive cause)

Bone Turnover Markers: An Optional Add-On

Serum C-telopeptide (CTX) reflects bone resorption; serum P1NP reflects bone formation. These markers are not required at every visit but can confirm treatment response 3-6 months after starting a bisphosphonate, before a repeat DEXA is informative. The International Osteoporosis Foundation and European Calcified Tissue Society recommend P1NP and CTX as reference markers for clinical trials and clinical practice.

Step 4: Medication Review

Your medication list does double duty at the annual evaluation: screen for drugs that harm bone, and confirm that any osteoporosis treatment you are on is still appropriate.

Drugs That Harm Bone

Several commonly prescribed drugs accelerate bone loss. Review these with your clinician:

• Glucocorticoids (any dose, any route, if used long-term)
• Aromatase inhibitors (letrozole, anastrozole, exemestane), used in hormone-receptor-positive breast cancer survivors
• Depot medroxyprogesterone acetate (Depo-Provera), associated with bone loss that mostly reverses after stopping
• Long-term proton pump inhibitors (impair calcium absorption)
• Antiepileptics (phenytoin, carbamazepine, which induce CYP450 and lower vitamin D)
• Selective serotonin reuptake inhibitors (some evidence of modest bone loss with long-term use)
• Levothyroxine at suppressive doses (relevant in thyroid cancer survivors)

Women on aromatase inhibitors have a 2-3 times higher rate of fracture compared to women on tamoxifen, according to the ATAC trial long-term follow-up. If you are a breast cancer survivor on an aromatase inhibitor, your annual osteoporosis evaluation warrants extra attention.

Current Osteoporosis Medications: Check Efficacy and Safety

| Medication | Class | Typical Duration | Annual Check | |---|---|---|---| | Alendronate | Bisphosphonate (oral) | 5 years, then reassess | Adherence, GI tolerability, eGFR | | Risedronate | Bisphosphonate (oral) | 5 years, then reassess | Same as alendronate | | Zoledronic acid | Bisphosphonate (IV) | 3 infusions, then reassess | eGFR before each infusion | | Denosumab | RANK-L inhibitor | Continuous (do not stop abruptly) | Calcium, eGFR, injection schedule | | Raloxifene | SERM | Long-term in some patients | VTE history, hot flash burden | | Teriparatide | PTH analogue (anabolic) | 24 months (lifetime limit) | Serum calcium, cancer history | | Abaloparatide | PTHrP analogue (anabolic) | 18 months (lifetime limit) | Serum calcium, injection site | | Romosozumab | Anti-sclerostin | 12 months (lifetime limit) | Cardiovascular risk, blood pressure |

Denosumab discontinuation warning. Unlike bisphosphonates, stopping denosumab without transitioning to a bisphosphonate causes rapid rebound bone loss and vertebral fracture risk. The European Medicines Agency flagged this in 2017, and multiple case series have documented vertebral fractures within 6-18 months of stopping denosumab. Never stop denosumab without a transition plan.

Step 5: Fall-Risk Assessment

Half of all hip fractures follow a fall. A DEXA scan measures bone strength, but falls are what translate that weakness into injury.

Validated Fall-Risk Screening Tools

The CDC STEADI (Stopping Elderly Accidents, Deaths, and Injuries) toolkit is the most widely used primary-care fall-risk screen. It includes a 3-item stay-independent questionnaire, gait speed, and the Timed Up and Go test.

At your annual visit, your clinician should ask:

1. Have you fallen in the past year?
2. Do you feel unsteady when walking or standing?
3. Are you worried about falling?

A "yes" to any of these triggers a full assessment.

Modifiable Fall Risk Factors in Postmenopausal Women

• Polypharmacy (four or more medications), especially sedatives, benzodiazepines, and anticholinergics
• Vitamin D deficiency (muscle weakness, not just bone loss)
• Visual impairment (annual eye exam matters)
• Orthostatic hypotension (common in women on antihypertensives)
• Home hazards (loose rugs, poor lighting, no grab bars)

A 2019 Cochrane review found that exercise programs, particularly tai chi and balance training, reduced fall rates by 23% in older adults. Referral to physical therapy or a structured exercise program is a legitimate prescription, not a suggestion.

Step 6: Calcium and Vitamin D Adequacy

Getting calcium and vitamin D right is foundational but consistently underdone.

Calcium Targets by Life Stage

| Life Stage | Recommended Dietary Calcium | |---|---| | Premenopausal women (19-50) | 1,000 mg/day | | Postmenopausal women (51+) | 1,200 mg/day | | Pregnant or lactating | 1,000 mg/day |

The Institute of Medicine recommends 1,200 mg/day of calcium for women over 50, with a tolerable upper intake of 2,500 mg/day from all sources combined. Food-first is preferred; supplements fill the gap. Calcium carbonate is better absorbed with food; calcium citrate works with or without food and is preferred after bariatric surgery or with achlorhydria.

Vitamin D Targets

The Endocrine Society recommends 1,500-2,000 IU/day of vitamin D3 for adults at risk of deficiency, including postmenopausal women. A serum 25-OH vitamin D above 30 ng/mL is generally considered sufficient for bone health, though some clinicians target 40-50 ng/mL.

Step 7: Hormone Therapy Considerations

Menopausal hormone therapy (MHT) is not a first-line osteoporosis treatment in women who are past 60 or more than 10 years from menopause onset. But for women in early postmenopause (under 60, within 10 years of menopause) who also have bothersome vasomotor symptoms, MHT addresses both problems simultaneously.

The WomanRx Early-Postmenopause Decision Framework for MHT and Bone:

• If you are under 60, within 10 years of your last period, AND have moderate-to-severe hot flashes: MHT is a reasonable first consideration, covering both symptom relief and bone protection.
• If you are over 60 or more than 10 years from menopause, with no vasomotor symptoms: MHT is generally not recommended for osteoporosis alone; use a bone-specific agent.
• If you have a history of estrogen-receptor-positive breast cancer: MHT is contraindicated; bisphosphonates or denosumab are the standard approach.
• If you had a premature surgical menopause: MHT until at least age 51 is recommended for both bone and cardiovascular protection.

The Menopause Society 2022 Hormone Therapy Position Statement confirms that MHT is effective for fracture prevention and is an appropriate choice for women under 60 or within 10 years of menopause who have no contraindications.

Who This Evaluation Is Right For (and Who Needs a Different Path)

Women Who Benefit Most From Annual Structured Evaluation

• Postmenopausal women with a diagnosis of osteoporosis or osteopenia on any treatment
• Women with a prior fragility fracture (wrist, vertebra, hip after low-impact trauma)
• Women on chronic glucocorticoids, aromatase inhibitors, or other bone-damaging drugs
• Women who had premature menopause (surgical or natural, before age 45)
• Breast cancer survivors on endocrine therapy

Women Who Need a Modified Approach

Perimenopausal women. Bone loss accelerates in the 2-3 years before the final menstrual period. DEXA may be appropriate earlier than age 65 if cycles are irregular and vasomotor symptoms suggest late perimenopause.

Women with chronic kidney disease. eGFR below 30-35 mL/min/1.73 m² changes almost every treatment option. Bisphosphonates are generally avoided; denosumab can be used with caution; activated vitamin D (calcitriol) replaces standard vitamin D supplementation.

Women with a history of bariatric surgery. Roux-en-Y gastric bypass and sleeve gastrectomy both impair calcium absorption. ASMBS guidelines recommend annual DEXA surveillance and higher calcium and vitamin D supplementation for women post-bariatric surgery.

Pregnancy, Lactation, and Contraception Considerations

Osteoporosis is primarily a postmenopausal diagnosis, but this section is relevant for perimenopausal women who still have reproductive potential and for women diagnosed with premenopausal osteoporosis.

Pregnancy and Osteoporosis Drugs

Most pharmacologic osteoporosis treatments carry significant fetal risk.

Bisphosphonates incorporate into bone for years after stopping. Animal data show fetal skeletal abnormalities. The FDA classifies bisphosphonates as Pregnancy Category C (old system), and the prescribing information for alendronate states it should be used during pregnancy only if the potential benefit justifies the potential risk. Women of reproductive age taking bisphosphonates should use reliable contraception and discuss the drug-holiday timeline with their clinician before attempting conception.

Denosumab is contraindicated in pregnancy. FDA labeling states denosumab may cause fetal harm based on animal data and the mechanism of RANK-L inhibition, which is required for normal lymph node development. Effective contraception is required during treatment and for at least five months after the last dose.

Teriparatide and abaloparatide have not been studied in human pregnancy. Animal studies show skeletal effects. Both are contraindicated in pregnancy.

Romosozumab is contraindicated in pregnancy based on animal reproductive toxicity data.

Lactation

Calcium homeostasis shifts during breastfeeding: women may lose 3-5% of bone mass over six months of exclusive breastfeeding, which largely recovers after weaning. This is normal physiology, not pathologic osteoporosis. Pharmacologic treatment is not indicated for lactation-associated bone loss in otherwise healthy women.

A Note on Transient Osteoporosis of Pregnancy

A rare condition, transient osteoporosis of the hip in late pregnancy or the early postpartum period, presents with hip pain and fragility fracture. Management is supportive (protected weight-bearing, calcium, vitamin D, physical therapy). Most cases resolve within six months.

Your Annual Evaluation Checklist: At a Glance

Use this at your next appointment.

Before the Visit

• [ ] Bring your previous DEXA report and T-scores
• [ ] List all medications, including supplements and over-the-counter drugs
• [ ] Note any new falls, back pain, or height loss
• [ ] Record your estimated daily dietary calcium intake

At the Visit: Tests and Measurements

• [ ] Height measurement (greater than 1.5-inch loss from peak height suggests vertebral fracture)
• [ ] DEXA scan if due (based on prior T-score and schedule)
• [ ] FRAX calculation updated with current age and BMD
• [ ] Lab panel: 25-OH vitamin D, calcium, creatinine, TSH, CBC
• [ ] Secondary cause workup if indicated

Medication Review

• [ ] Check adherence to current osteoporosis medication
• [ ] Review bone-harming drugs and consider deprescribing or mitigating
• [ ] Confirm denosumab injection schedule (every 6 months; no gaps)
• [ ] Reassess bisphosphonate drug holiday eligibility at 5 years (oral) or 3 years (IV)

Lifestyle and Risk

• [ ] Fall-risk screen (STEADI 3 questions)
• [ ] Calcium and vitamin D intake confirmed adequate
• [ ] Exercise: weight-bearing and resistance training reviewed
• [ ] Alcohol and smoking status documented

Decisions to Make Together

• [ ] Start treatment if FRAX thresholds met
• [ ] Adjust or switch medication if DEXA shows ongoing loss on treatment
• [ ] Discuss hormone therapy eligibility in early postmenopause
• [ ] Referral to physiatry or physical therapy if fall risk is elevated